Search
Zegruvirimat
go.drugbank.com/drugs/DB21535ExperimentalZegruvirimat is a small molecule drug. The usage of the INN stem '-virimat' in the name indicates that Zegruvirimat is a antiviral, disruptor of viral maturation.
Anizatrectinib
go.drugbank.com/drugs/DB21536ExperimentalAnizatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Anizatrectinib is a tropomyosin receptor kinase (TRK) inhibitor.
Pelecopan
go.drugbank.com/drugs/DB21573ExperimentalPelecopan is a small molecule drug. The usage of the INN stem '-copan' in the name indicates that Pelecopan is a complement receptor antagonist/complement inhibitor.
Envonalkib
go.drugbank.com/drugs/DB21585ExperimentalEnvonalkib is a small molecule drug. The usage of the INN stem '-alkib' in the name indicates that Envonalkib is a ALK (anaplastic lymphoma kinase) inhibitor.
Zurletrectinib
go.drugbank.com/drugs/DB21601ExperimentalZurletrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Zurletrectinib is a tropomyosin receptor kinase (TRK) inhibitor.
Rolusafine
go.drugbank.com/drugs/DB21617ExperimentalRolusafine is a small molecule drug. The usage of the INN stem '-afine' in the name indicates that Rolusafine is a antifungal squalene mono-oxygenase inhibitor.
Merigolix
go.drugbank.com/drugs/DB21628ExperimentalMerigolix is a small molecule drug. The usage of the INN stem '-golix' in the name indicates that Merigolix is a gonadotropin releasing hormone (GnRH) antagonist.
Lerzeparib
go.drugbank.com/drugs/DB21650ExperimentalLerzeparib is a small molecule drug. The usage of the INN stem '-parib' in the name indicates that Lerzeparib is a poly-ADP-Ribose polymerase inhibitor.
Nurandociguat
go.drugbank.com/drugs/DB21720InvestigationalNurandociguat is a small molecule drug. The usage of the INN stem '-ciguat' in the name indicates that Nurandociguat is a guanylate cyclase activator and stimulator.
Coronavirus-Like Particle COVID-19 Vaccine
go.drugbank.com/drugs/DB15852ExperimentalThe Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. … A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged